Long-term safety of brodalumab compared with other psoriasis treatments
Follows adults with moderate-to-severe psoriasis treated with brodalumab or other therapies.
Plain-language title generated from the registry record
Registry title: LTS of Siliq vs. Other Therapies Treating of Adults With Moderate-to-Severe Psoriasis
Key facts
- Where
- Bridgewater, United StatesSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 99 years old?
Source: NCT03254667, who can take part
Where in United States
- RegistryBridgewater, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Bausch Health Americas, Inc.
- Trial code
- NCT03254667
- Record updated
- 16 September 2025
- Original description
Prospective, Observational Study to Assess the Long-Term Safety of Brodalumab Compared with Other Therapies in the Treatment of Adults with Moderate-to-Severe PsoriasisRead full original descriptionShow less
Prospective, Observational Study Brodalumab Compared With Other Therapies in the Treatment of Adults With Moderate-to-Severe Psoriasis Who Are Candidates for Systemic Therapy or Phototherapy in the Course of Actual Clinical Care
Prospective, Observational Study to Assess the Long-Term Safety of Brodalumab Compared with Other Therapies in the Treatment of Adults with Moderate-to-Severe Psoriasis
Inclusion: Diagnosis and main criteria for inclusion: a subject must have moderate to severe psoriasis diagnosed by a dermatologist; Must be at least 18 years of age or older; Started on or switched to a systemic psoriasis treatment within the previous 12 months. FDA-approved biologic treatments and select non-biologic treatments (eg, methotrexate, cyclosporine, or apremilast only) are permitted.
Exclusion: The subject is participating or planning to participate in a clinical trial with a non-marketed or marketed investigational drug (i.e. Phase I-IV drug trial); The subject is restarting the eligible medication less than 12 months since receiving the last dose; The subject is unable or unwilling to provide informed consent to participate in the registry.